Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: "The water affects everyone," she said, which is why she believes her job is so important. Reese is studying public health and environmental health at East Carolina University in North Carolina. She will be an intern for the East Shore department, working on the Connecticut shoreline until the end of July. Reese spends her Tuesday mornings driving around to all the public and private natural swimming areas in Branford, North Branford and East Haven, collecting water samples and putting them on ice in her purple cooler. The samples are then collected by state Department of Public Health couriers and brought to the state lab in Rocky Hill for testing. Water quality testing has always been a priority for the East Shore department every summer, but this year, Alex Cinotti, the assistant director of health, has something he's trying to prove. Every year, from Memorial Day to Labor Day, the department collects weekly water samples from 12 water bodies used for swimming, both freshwater and saltwater, to ensure bacteria levels are low enough for public safety. Samples are collected and tested once a week, and as long as bacteria levels fall below state-determined risk levels, the beaches and other water bodies remain open. This year, however, Cinotti would like to take the sampling a step further to show a direct correlation between rainfall and elevated bacteria levels, he said, as rain will often wash contaminants into public waters and cause bacteria levels to rise. "This is our opportunity to take samples and establish a pattern," Cinotti said. "Bacteria is bacteria and we consider it pathogenic." As such, in addition to the weekly sampling of water, Cinotti said that the department is collecting samples after heavy rains to see if bacteria levels rise after rainfall. This kind of analysis could not be done last summer, Cinotti said, because there were few rain events due to the drought. On the state level, the Department of Energy and Environmental Protection will close public beaches after a significant amount of rainfall, in anticipation of potentially higher bacteria levels. Scott Szalkiewicz, a health program supervisor for the state Health Department, told the Register last summer that because samples take 24 hours to process, it's helpful to be able to close beaches before test results come in when officials believe bacteria levels will be high based on the amount of rain and visual indicators. The East Shore District Health Department serves Branford, North Branford and East Haven. The 12 bathing waters surveyed each week include the east and west East Haven beaches, the Clark Avenue beach, Branford Point, Stony Creek, Hotchkiss Grove, Turtle Bay, Sunrise Cove, Lanphier Cove, Cedar Lake, Linsley Lake and Clear Lake. According to water quality records from the East Shore District Health Department in 2016, there was only one time when bacteria levels reached a level at which one of the beaches had to close. Sunrise Cove reached a level of 1,000 colonies of bacteria in the sample of 100 milliliters of water on Aug. 2, 2016, according to the records. Cinotti said that the safe levels for salt water are 104 colonies of bacteria per 100 milliliters of water and 235 colonies for fresh water per 100 milliliters of water. Some things that cause heightened bacteria levels include wild animal and dog feces, sewer overflows and leaks, Cinotti said. Rain may wash contaminants such as sewer overflows, nitrogen-rich pollutants and goose and dog feces into the Sound and other bathing water bodies. Potential health risks from swimming in water with high levels of bacteria include possible infections to open wounds and gastrointestinal illness when water is accidentally swallowed, Cinotti said. He added that it's possible swimmers could contract eye- or ear-related illnesses from high levels of bacteria. "We really need to protect children," Cinotti said. "They are more vulnerable than adults." ___ Online: http://bit.ly/2rFTp4s ___ Information from: New Haven Register, http://www.nhregister.com Claim: Officials study link between rain and bacteria in water.

A: For Kellyn Reese, waking up on Tuesday mornings and going to the beach because it's her job is a nice perk of being a summer intern at the East Shore District Health Department.
****
Q: Paragraph: Roughly half of Yellowstone's 4,600 bison are estimated to have been exposed to brucellosis, a bacterial infection that can sometimes cause cows and bison to miscarry. Worries that infected bison may endanger cattle in states such as Montana that border Yellowstone had prompted the powerful ranching lobby to endorse biobullets - absorbable projectiles packed with vaccine. They would cut disease rates among bison by as much as 35 percent over 30 years. The proposal was the latest decades-long efforts to ease conflicts between livestock interests and wildlife advocates over management of Yellowstone bison. Park officials said they decided against the remote vaccination program because of its $9 million price tag, questions about its effectiveness and the possible impact on the millions of visitors who flock to the park to view iconic Western wildlife like bison. The measure would have required shooting the animals once a year for three decades, raising questions about how increased human interaction could affect bison within the wild herd. "We have concerns about how that repeated contact might impact bison behavior and their visibility to park visitors," said Yellowstone spokesman Al Nash. Nash said there was no documented case of wild bison transmitting brucellosis to cattle, which he said signifies the success of existing measures designed to separate the park's herd from domestic livestock. Those practices include returning bison that leave the park, testing and vaccinating bison that leave Yellowstone, and slaughtering some infected animals. Errol Rice, executive vice president of the Montana Stockgrowers Association, said the threats posed by infected bison to Montana's brucellosis-free certification, which protects the market value of cattle, warranted using biobullets. He said the program would have lessened the public outcry that erupts when wandering bison are corralled and shipped to slaughterhouses. "The capture and removal of bison has been a challenging issue for the park and Montana. Remote vaccination would have helped alleviate the public relations burden we have to deal with when bison migrate out of Yellowstone," he said. Stephany Seay, spokeswoman for Buffalo Field Campaign, a bison advocacy group, applauded the park's decision not to shoot bison with vaccine. "It was a mismanagement scheme based on a livestock model. We don't vaccinate skunks against rabies or mosquitoes against West Nile virus," she said. Claim: Yellowstone managers reject vaccinating bison with biobullets.

A: Yellowstone National Park managers have rejected a plan to use air rifles to shoot the nation's last herd of purebred bison with so-called biobullets containing a vaccine against a cattle disease, in a decision that has riled the U.S. livestock industry.
****
Q: Paragraph: The decision comes less than two weeks after Medtronic Inc said it was halting clinical trials for its high blood pressure device after the treatment, known as renal denervation, failed to prove effective in a key U.S. study. Medtronic's move surprised many observers. The devices, which are not available in the United States, take a new approach to treating hypertension and are aimed at patients resistant to traditional drug-based therapies. Some analysts had predicted the technology, which works by deadening nerves in the kidneys, could evolve into a $2 billion market by providing an alternative to drug therapy. Covidien said the decision to exit the business was a result of its regular review of strategic programs. "The company took a close look at the renal denervation market and realized it really is growing much slower than expected," said Covidien spokesman Peter Lucht. He declined to comment on whether Medtronic's study outcome played a role in his company's decision. S&P Capital analyst Phillip Seligman said the failed clinical trial of Medtronic's product likely influenced Covidien's decision but noted sales of the device were modest. He maintained a "strong buy" rating on Covidien shares. Covidien's device, called OneShot, was sold in Europe and the Middle East. In Europe, where the product was approved in February 2012, adoption of such devices has run into reimbursement hurdles as governments have been reluctant to pay for the new technology. The devices work by creating tiny scars along nerves in the kidneys - organs that play a pivotal role in regulating blood pressure by sending signals to the brain that can cause blood vessels to constrict. Following its decision to halt clinical studies of its renal denervation system, Medtronic said it would form an independent panel of experts to make recommendations on the future of the product, called Symplicity. Medtronic continues to sell the product in 85 countries. It has been approved in Europe since April 2010. St Jude Medical Inc and Boston Scientific Corp also sell renal denervation products in Europe and other markets. Boston Scientific acquired its system through the purchase of Vessix Vascular Inc in November 2012. A Medtronic spokeswoman said it was too soon to determine the next steps for Symplicity. "We don't know if we would consider another clinical trial. We don't know anything yet," said spokeswoman Wendy Dougherty. Covidien said it expects to record after-tax charges of $20-$25 million as a result of exiting the program. The company's shares fell 1 cent to $68.19 on Tuesday. (This January 21 story was corrected to fix name of Medtronic hypertension product to Symplicity, not Ardian, paragraphs 9, 12) Claim: Covidien to stop selling hypertension device.

A:
Covidien Plc said it would stop making a device for treating high blood pressure due to weak demand for the product, raising more doubts about the future of the novel technology.
****